Trial · NCT07161336
Role of Methotrexate in Ultrasound Proven Synovitis in Primary Knee OA
NCT07161336, Phase 2, Recruiting, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Role of Methotrexate in Ultrasound Proven Synovitis in Primary Knee OA. Trials, record NCT07161336. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07161336
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Role of Methotrexate in Ultrasound Proven Synovitis in Primary Knee OA
- NCT number
- NCT07161336
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 70 participants, estimated
- Lead sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
- Conditions
- Osteo Arthritis of the Knee, Synovitis of Knee, Methotrexate
- Interventions
- Methotrexate (MTX), Placebo
- First posted
- 2025-09-08
- Last updated
- 2025-09-12
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | To assess the role of Methotrexate to change the functional status with Western Ontario and McMaster Universities Osteoarthritis Index in patients with ultrasound proven synovitis associated with primary knee Osteoarthritis. | 6 months | This Western Ontario and McMaster Universities Osteoarthritis Index have 24 questions divided in 3 domains ( PAIN, Stiffness, Difficulty in performing daily activities) each of the 24 questions having a visual analog scale of 0-10.Patients will score themselves between 0-10 for each question . So the minimum score will be 0 and the maximum score will be 240 .The higher the number more severe the condition. |
| Secondary | changes in synovitis by Outcome Measures in Rheumatology (OMERACT) scoring in patients with primary knee OA. | 6 months | Outcome Measures in Rheumatology (OMERACT) scoring of USG findings of knee joint have 7 domains , each of the domains will be scored based on the ultrasound findings like the following. USG findings 1. Synovitis 0 1 2 3 2. Cartilage damage 0 1 2 3 3. Meniscal damage 0 1 2 4. Osteophytes : 0 1 2 3 5. Synovial hypertrophy : Present=1or Absent=0 6. Effusion : Present=1 or Absent=0 7. Synovial PD signal : Present=1 or Absent=0 The higher the number more severe the condition |
| Secondary | Change in Quality of life through 12-item Short-Form Health Survey (SF-12) in patients with primary knee OA | 6 months | The 12-Item Short Form Survey (SF-12v2) is a 12- item questionnaire used to assess generic health outcomes from a patient's perspective. SF-12 is used to measure physical and mental components of health in patients with any chronic illness on a broad range of functional domains. The SF-12 consists of a subset of 12 items drawn from SF-36. covering the same eight domains of health outcomes measuring physical functioning (PF), role physical (RP, physical health problems), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role emotional (RE, emotional problems) and mental health (MH). Higher scores represent better health status. Score more than 50 is better and below 50 is considered lower than average. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07161336
GET https://conductscience.org/api/trials/v1/NCT07161336/registered